The company currently has a product candidate in the late-discovery phase, an EGFR-targeting drug for lung cancer that would go after a resistance mechanism against existing kinase inhibitors.
Article Source: Aro Biotherapeutics draws $13M in startup investment to target centyrin proteins.
0 Comments